At a glance
ClinicalIndex Comparison RecordN/ACompleted· 549 enrolled
Drug / intervention
crizotinib +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Real-world Study of Non-small Cell Lung Cancer Treatment With ALK-tyrosine Kinase Inhibitors (ALK TKI) in Sweden: Drug Sequencing, Treatment Duration and Overall Survival - A Retrospective Study Using Swedish Register Data
In Brief
An observational study evaluating crizotinib, alectinib, and 3 other interventions for ALK-positive NSCLC. Completed, enrolled 549 participants across 1 site.
Detailed Summary
This study aims to explore for the first time how the different ALK TKIs have been sequenced in real-world clinical practice and with which outcomes for Swedish lung cancer patients
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsALK-positive NSCLC
CountriesSweden
Collaborators--
Timeline
N/ACompletedFinished
202120222023202420252026
First PostedNov 2020
Enrollment StartDec 2020
Primary CompletionMar 2021
TodayJul 2026
First PostedNov 30, 2020
Enrollment StartDec 14, 2020
Primary CompletionMar 15, 2021
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 5.6 years ago
Interventions
crizotinibdrug
as provided in real world practice
alectinibdrug
as provided in real world practice
brigatinibdrug
as provided in real world practice
ceritinibdrug
as provided in real world practice
lorlatinibdrug
as provided in real world practice